Hims & Hers Health (NYSE:HIMS) Issues Earnings Results, Misses Estimates By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.03), FiscalAI reports. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The firm had revenue of $890.37 million for the quarter, compared to analyst estimates of $892.88 million.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded down $3.10 during mid-day trading on Monday, reaching $22.90. 41,031,904 shares of the company were exchanged, compared to its average volume of 22,156,463. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $42.70. The firm’s 50-day simple moving average is $28.43 and its two-hundred day simple moving average is $26.94. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The firm has a market cap of $5.34 billion, a PE ratio of -36.34 and a beta of 2.53.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 29,277 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total transaction of $876,846.15. Following the completion of the sale, the chief financial officer directly owned 236,527 shares of the company’s stock, valued at $7,083,983.65. This trade represents a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of Hims & Hers Health stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares in the company, valued at approximately $1,363,563.85. This trade represents a 25.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 133,905 shares of company stock valued at $3,826,977. Company insiders own 11.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup lowered their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Barclays reduced their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health in a research note on Friday, September 11th. They set a “neutral” rating and a $32.00 price target for the company. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Truist Financial raised their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research report on Monday, August 24th. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.